ArticleJournal of medical biochemistry2025
Effect of glycemic gap on prognosis and complications in vulnerable period of acute heart failure.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the effect of glycemic gap on the prognosis and complications of heart failure in patients with acute heart failure. Methods: A total of 100 patients with acute heart failure admitted to our hospital from January 2022 to August 2023 were retrospectively selected, and the patients were divided into two groups according to their prognosis, the good prognosis group (n=58) and the poor prognosis group (n=42). The general data of the two groups were compared, and the influencing factors on the prognosis of patients with acute heart failure during the fragile period were analyzed by multi-factor Logistics regression. ROC analyzed the predictive value of blood sugar gap on the prognosis of acute heart failure patients during the vulnerable period of heart failure, and compared the incidence of complications between the two groups of patients.. Results: The blood glucose gap, NT-proBNP, Ang II, hscTn, and SCR in patients with good prognosis were lower than those in patients with poor prognosis, and LVEF and hemoglobin were higher than those in patients with poor prognosis (P<0.05). Multivariate Logistics regression analysis results showed that blood glucose gap, NTproBNP, AngII, hs-cTn, SCR, LVEF, and hemoglobin were independent influencing factors on the prognosis of acute heart failure patients during the vulnerable period of heart failure (P<0.05), ROC analysis results showed that the area under the curve of the value of blood sugar gap in the prognosis of acute heart failure patients during the vulnerable period of heart failure was 0.6071,(95% CI: 0.3107~0.9035), Youden=0.89, at this time, the sensitiv ity was 92.8 and the specificity was 97.1. The complication rate in the good prognosis group (1.72%) was significantly lower than that in the poor prognosis group (16.67%). Conclusions: Glycemic gap is related to the prognosis and complications of heart failure in patients with acute heart failure. Hyperglycemia gap will affect the prognosis of heart failure in patients with acute heart failure, resulting in poor prognosis and increasing the incidence of complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.